Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1997 2
1999 4
2000 9
2001 5
2002 4
2003 2
2004 4
2005 4
2006 4
2007 5
2008 7
2009 1
2010 2
2011 1
2012 5
2014 4
2015 5
2016 15
2017 6
2018 10
2019 8
2020 6
2021 6
2022 11
2023 6
2024 3
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Endocrine. 2021 Feb;71(2):502-513. doi: 10.1007/s12020-020-02475-2. Epub 2020 Oct 14. Endocrine. 2021. PMID: 33052555 Free PMC article.
PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). ...CONCLUS …
PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved pr …
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks. ...The most comm …
Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United St …
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK. Gadelha MR, et al. J Clin Endocrinol Metab. 2024 Dec 18;110(1):228-237. doi: 10.1210/clinem/dgae385. J Clin Endocrinol Metab. 2024. PMID: 38828555 Free PMC article. Clinical Trial.
METHODS: This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had IGF-I 1.0 times the upper limit of normal ( ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected …
METHODS: This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had IGF-I 1.0 times the upper …
Lanreotide.
[No authors listed] [No authors listed] 2026 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2026 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 31145576 Free Books & Documents. Review.
The excretion of lanreotide into breastmilk has not been studied. However, because it has a high molecular weight of 1096 daltons it is likely to be poorly excreted into breastmilk and it is a peptide that is likely digested in the infant's gastrointestinal tract, so it is …
The excretion of lanreotide into breastmilk has not been studied. However, because it has a high molecular weight of 1096 daltons it …
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.
Ferone D, Freda P, Katznelson L, Gatto F, Kadioğlu P, Maffei P, Seufert J, Silverstein JM, Spencer-Segal JL, Isaeva E, Dreval A, Harrie M, Svedberg A, Tiberg F. Ferone D, et al. J Clin Endocrinol Metab. 2025 May 19;110(6):1729-1739. doi: 10.1210/clinem/dgae707. J Clin Endocrinol Metab. 2025. PMID: 39378125 Free PMC article. Clinical Trial.
Standard of care (SoC; octreotide long-acting repeatable or lanreotide autogel) treatment typically requires healthcare provider administration. CAM2029, a novel subcutaneous octreotide depot with increased bioavailability using FluidCrystal technology, enables self …
Standard of care (SoC; octreotide long-acting repeatable or lanreotide autogel) treatment typically requires healthcare provider admi …
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT. Wolin EM, et al. J Gastrointest Cancer. 2016 Dec;47(4):366-374. doi: 10.1007/s12029-016-9866-9. J Gastrointest Cancer. 2016. PMID: 27619395 Free PMC article. Review.
This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhi …
This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health …
Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P, Phan AT, Adelman DT, Iwasaki M. Ryan P, et al. Clin J Oncol Nurs. 2016 Dec 1;20(6):E139-E146. doi: 10.1188/16.CJON.E139-E146. Clin J Oncol Nurs. 2016. PMID: 27857269 Review.
They are effective for a range of gastroenteropancreatic NETs (GEP-NETs). Lanreotide depot (Somatuline ) is an SSA that is approved for the treatment of GEP-NETs to improve progression-free survival (PFS). ...Nurses cited several benefits to using lanreoti …
They are effective for a range of gastroenteropancreatic NETs (GEP-NETs). Lanreotide depot (Somatuline ) is an SSA that …
Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Paulson S, et al. Oncol Ther. 2022 Dec;10(2):463-479. doi: 10.1007/s40487-022-00208-1. Epub 2022 Sep 22. Oncol Ther. 2022. PMID: 36136274 Free PMC article.
This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting. ...One approved treatment for patients whose tumor cannot be …
This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot …
Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.
Sagvand BT, Khairi S, Haghshenas A, Swearingen B, Tritos NA, Miller KK, Klibanski A, Nachtigall LB. Sagvand BT, et al. Pituitary. 2016 Aug;19(4):437-47. doi: 10.1007/s11102-016-0724-3. Pituitary. 2016. PMID: 27155600
Few studies have evaluated the long-term efficacy and safety of lanreotide depot beyond 2 years. The goal of this study was to provide a long-term longitudinal assessment of efficacy and safety of lanreotide depot in lanreotide responders compar …
Few studies have evaluated the long-term efficacy and safety of lanreotide depot beyond 2 years. The goal of this study was to …
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET).
Morse MA, Crosby EJ, Halperin DM, Uronis HE, Hsu SD, Hurwitz HI, Rushing C, Bolch EK, Warren DA, Moyer AN, Lowe ME, Niedzwiecki D. Morse MA, et al. J Neuroendocrinol. 2025 Apr;37(4):e13496. doi: 10.1111/jne.13496. Epub 2025 Feb 11. J Neuroendocrinol. 2025. PMID: 39933708 Clinical Trial.
While performing a study of immune checkpoint blockade with the anti-PD-1 antibody pembrolizumab combined with the somatostatin analogue (SSA) lanreotide in patients with low- and intermediate-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), we studied whethe …
While performing a study of immune checkpoint blockade with the anti-PD-1 antibody pembrolizumab combined with the somatostatin analogue (SS …
136 results